99% Purity Pharmaceutical Raw Powder Gefitinib CAS 184475-35-2

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: TGY022019042808
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Adult
• State: Solid
• Purity: >99%
• Product Name: Gefitinib
• Appearance: White Powder
• Specificcation: 99%
• CAS No.: 184475-35-2
• Grade: Pharmaceuticals Grade
• Shelf Life: 2 Years
• Storage: Cool Dry Place
• Shipping Time: Within 3-7 Working Days
• Transport Package: Foil Bag, Box, Drum
• Specification: 99% min
• Trademark: TGY
• Origin: China
• HS Code: 3001200010
• Production Capacity: 1500kg/Month

Product Description

<sub>99% Purity Pharmaceutical Raw Powder Gefitinib CAS 184475-35-2:

Gefitinib is the first selective inhibitor of epidermal growth   factor receptor's (EGFR) tyrosine kinase domain. Thus gefitinib is an EGFR inhibitor. The target protein (EGFR) is a member of a family of receptors (ErbB) which includes Her1(EGFR), Her2(erb-B2), Her3(erb-B3) and Her4 (Erb-B4). EGFR is overexpressed in the cells of certain types of human carcinomas - for example in lung and breast cancers. This leads to inappropriate activation of the anti-apoptotic Ras signalling cascade, eventually leading to uncontrolled cell proliferation. Research on gefitinib-sensitive non-small cell lung cancers has shown that a mutation in the EGFR tyrosine kinase domain is responsible for activating anti-apoptotic pathways.These mutations tend to confer increased sensitivity to tyrosine kinase inhibitors such as gefitinib and erlotinib. Of the types of non-small cell lung cancer histologies, adenocarcinoma is the type that most often harbors these mutations. These mutations are more commonly seen in Asians, women, and non-smokers (who also tend to more often have adenocarcinoma).

Gefitinib inhibits EGFR tyrosine kinase by binding to the adenosine triphosphate (ATP)-binding site of the enzyme.Thus the function of the EGFR tyrosine kinase in activating the anti-apoptotic Ras signal transduction cascade is inhibited, and malignant cells are inhibited.</sub>

Items of analysis	Specification	Results
Appearance	White to off-white powder	off-White powder
Identifcation	HPLC(RT)	Complies
Loss on drying	≤ 0.5%	0.13%
Residue on ignition	≤0.,1%	0.1%
Max Single Impurity	≤ 0.10 %	0.09%
Total Impurity	≤.1.0%	0.24%
Purity(HPLC)	≥99%	99.76%
Conclusion	Qualified